Identification of reproducible metabolites for Parkinson’s Disease diagnosis using clinical data and computational modelling
Objective: To identify replicated metabolic markers of Parkinson’s Disease (PD) diagnosis from metabolomic studies and predict additional metabolic markers using computational metabolic modelling. Background: Reported metabolic markers of…The effect of anti- Parkinson’s disease granules and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine -induced Parkinson’s disease
Objective: To investigate the effect of anti- Parkinson’s disease (anti-PD granules) and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine( MPTP )-induced PD. Background:…Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment
Objective: To assess TDIS and global AIMS measures change trajectories using data from KINECT-4, an open-label 52-week trial assessing valbenazine in TD [1] Background: AIMS…The Short Duration Response and Long Duration Response to L-Dopa are Needed to Restore Vigor-Motivation Coupling in Parkinson Disease
Objective: To assess the relationship between the Short Duration Response (SDR) and Long Duration Response (LDR) to L-Dopa therapy in Parkinson disease (PD) and restoration…Neuromelanin related 7T MRI of the locus coeruleus differs between Parkinson’s disease and controls
Objective: To compare the signal intensity of the substantia nigra and locus coeruleus on Magnetization Transfer 7T MRI between PD patients and healthy controls (HC)…Proteomic profiles analysis of plasma exosomes and WBC reveals news insights of PD patients classified into H&Y clinical stage
Objective: To perform a comparative proteomic analysis of WBC and exosomes in samples from PD patients and to compare with healthy controls (HC) using a…Effects of a small molecule angiotensin IV analog on Huntington’s disease animal model
Objective: The present study was designed to test if N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (AngIV-6a), an angiotensin IV analog, could attenuate 3-nitropropionic acid-induced Huntington’s disease-like symptoms in…Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study – results of the Belgian subgroup
Objective: The primary objective of the study was to evaluate the proportion of Parkinson’s Disease (PD) patients in Movement Disorder Centers with Advanced Parkinson’s Disease…Improving inpatient medication management in hospitalized Parkinson’s patients
Objective: Develop a process for Parkinson's patients to provide individualized medication management to reduce length of stay,, mortality, 30-day readmissions, and increase patient satisfaction. Background:…The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
Objective: To assess the effect of the metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM) AZD8529 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs)…
- « Previous Page
- 1
- …
- 173
- 174
- 175
- 176
- 177
- …
- 186
- Next Page »